Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?

A. J. Heffernan,A. Germano,F. B. Sime,Jason A. Roberts,E. Kimura
DOI: https://doi.org/10.1007/s00228-019-02694-1
2019-06-01
European Journal of Clinical Pharmacology
Abstract:<h3>Purpose</h3><p>Vancomycin is commonly used for the management of severe infections; however, vancomycin dosing may be challenging in critically ill patients. This observational study aims to describe the population pharmacokinetics of vancomycin in adult patients with sepsis or septic shock.</p><h3>Methods</h3><p>A single-centre retrospective review of adult patients with sepsis or septic shock receiving vancomycin with therapeutic drug monitoring was undertaken. Blood samples taken 1 h after the vancomycin infusion cessation and 30 min prior to the next dose were assayed using the Vitros Crea Slide method. Vancomycin concentrations determined on different days were included. A pharmacokinetic model was developed using Pmetrics for R. Monte Carlo dosing simulations were performed using the final model.</p><h3>Results</h3><p>Vancomycin concentrations were available for 27 adult patients admitted to the intensive care unit with sepsis or septic shock. A one-compartment pharmacokinetic model with inter-occasion variability of clearance and volume of distribution before and after 72 h adequately described the data. Creatinine clearance normalized to body surface area was included as a covariate on vancomycin clearance. The clearance and volume of distribution within 72 h of admission were 7.29 L/h and 54.20 L, respectively. Monte Carlo simulations suggested that for patients with a creatinine clearance of ≥ 80 mL/min/1.73 m<sup>2</sup>, vancomycin doses of ≥ 2 g every 8 h are required to consistently achieve key therapeutic targets.</p><h3>Conclusions</h3><p>Vancomycin doses ≥ 2 g every 8 h in adult patients with sepsis or septic shock with a creatinine clearance ≥ 80 mL/min/1.73 m<sup>2</sup> are likely needed to achieve an optimal therapeutic exposure.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?